Polyneuron Pharmaceuticals, a Switzerland-based autoimmune diseases treatment developer spun out from University of Basel, closed a Sfr3.1m ($3.1m) funding round on Monday led by life sciences investment firm Eva Basel.
Financial services firm Zürcher Kantonalbank (ZKB) and unnamed private investors also participated in the second close, which followed Eva Basel, ZKB and private investors committing $3m in 2016.
Founded in 2014, Polyneuron Pharmaceuticals is working on therapies for autoimmune diseases using a platform called Antibody-Catch that designs drugs for autoantibodies,…